retatrutide clinical trials retatrutide mechanism First phase 3 data, a Triumph of Science! Perceived benefits of treatment for

Giving exogenous GLP-1 analogues or increasing endogenous GLP-1 levels can enhance the signaling of GLP-1R, and the activation of GLP-1R can effectively inhibit glucagon secretion in human body

Ethics declarations Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Are symptoms affecting the patient's ability to continue treatment

Regular follow-up appointments are essential during GLP-1 therapy, typically aligning with the medication's titration schedule (often every 4 weeks initially) and as clinically indicated

Pending successful completion, FDA approval could come as early as 2027, which would make retatrutide the first approved triple-agonist medication